{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T22:33:50Z","timestamp":1788734030304,"version":"build-2803163510"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T00:00:00Z","timestamp":1652400000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T00:00:00Z","timestamp":1652400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["843001805"],"award-info":[{"award-number":["843001805"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>Standard surgical treatment of advanced-stage ovarian carcinoma with electrosurgery cannot always result in complete cytoreductive surgery (CRS), especially when many small metastases are found on the mesentery and intestinal surface. We investigated whether adjuvant use of a neutral argon plasma device can help increase the complete cytoreduction rate.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Patients and Methods<\/jats:title>\n                <jats:p>327 patients with FIGO stage IIIB\u2013IV epithelial ovarian cancer (EOC) who underwent primary or interval CRS were randomized to either surgery with neutral argon plasma (PlasmaJet) (intervention) or without PlasmaJet (control group). The primary outcome was the percentage of complete CRS. The secondary outcomes were duration of surgery, blood loss, number of bowel resections and colostomies, hospitalization, 30-day morbidity, and quality of life (QoL).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Complete CRS was achieved in 119 patients (75.8%) in the intervention group and 115 patients (67.6%) in the control group (risk difference (RD) 8.2%, 95% confidence interval (CI) \u20130.021 to 0.181; <jats:italic>P<\/jats:italic> = 0.131). In a per-protocol analysis excluding patients with unresectable disease, complete CRS was obtained in 85.6% in the intervention group and 71.5% in the control group (RD 14.1%, 95% CI 0.042 to 0.235; <jats:italic>P<\/jats:italic> = 0.005). Patient-reported QoL at 6 months after surgery differed between groups in favor of PlasmaJet surgery (95% CI 0.455\u20138.350; <jats:italic>P<\/jats:italic> = 0.029). Other secondary outcomes did not differ significantly.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Adjuvant use of PlasmaJet during CRS for advanced-stage ovarian cancer resulted in a significantly higher proportion of complete CRS in patients with resectable disease and higher QoL at 6 months after surgery. (Funded by ZonMw, Trial Register NL62035.078.17.)<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial Registration<\/jats:title>\n                <jats:p>Approved by the Medical Ethics Review Board of the Erasmus University Medical Center Rotterdam, the Netherlands, NL62035.078.17 on 20-11-2017. Recruitment started on 30-1-2018.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1245\/s10434-022-11763-2","type":"journal-article","created":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T06:04:54Z","timestamp":1660197894000},"page":"4833-4843","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Adjuvant Use of PlasmaJet Device During Cytoreductive Surgery for Advanced-Stage Ovarian Cancer: Results of the PlaComOv-study, a Randomized Controlled Trial in The Netherlands"],"prefix":"10.1245","volume":"29","clinical-trial-number":[{"clinical-trial-number":"ntr-6203507817","registry":"10.18810\/dutch-trial-register"}],"author":[{"given":"G. M.","family":"Nieuwenhuyzen-de Boer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Hofhuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Reesink-Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Willemsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I. A.","family":"Boere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I. G.","family":"Schoots","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. M. J.","family":"Piek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. N.","family":"Hofman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. J.","family":"Beltman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. J.","family":"van Driel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. M. J.","family":"Werner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Baalbergen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. M. L. D.","family":"van Haaften-de Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Dorman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Haans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Nedelcu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. C.","family":"Ewing-Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. J.","family":"van Beekhuizen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,13]]},"reference":[{"issue":"3","key":"11763_CR1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"11763_CR2","first-page":"1521","volume":"33","author":"I Steinberga","year":"2019","unstructured":"Steinberga I, Jansson K, Sorbe B. Quality Indicators and Survival Outcome in Stage IIIB-IVB Epithelial Ovarian Cancer Treated at a Single Institution. In vivo (Athens, Greece). 2019;33(5):1521\u201330.","journal-title":"In vivo (Athens, Greece)."},{"key":"11763_CR3","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1002\/cncr.24149","volume":"115","author":"A du Bois","year":"2009","unstructured":"du Bois A, Reuss A, Pujade-Lauraine E, et al. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d\u2019Investigateurs Nationaux Pour les Etudes des Cancers de l\u2019Ovaire (GINECO). Cancer. 2009;115:1234\u201344.","journal-title":"Cancer."},{"key":"11763_CR4","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1056\/NEJM199503093321002","volume":"332","author":"ME van der Burg","year":"1995","unstructured":"van der Burg ME, van Lent M, Buyse M, et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med. 1995;332:629\u201334.","journal-title":"N Engl J Med."},{"key":"11763_CR5","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1056\/NEJMoa0908806","volume":"363","author":"I Vergote","year":"2010","unstructured":"Vergote I, Trop\u00e9 CG, Amant F, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363:943\u201353.","journal-title":"N Engl J Med."},{"issue":"5","key":"11763_CR6","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1200\/JCO.2002.20.5.1248","volume":"20","author":"RE Bristow","year":"2002","unstructured":"Bristow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002;20(5):1248\u201359.","journal-title":"J Clin Oncol"},{"issue":"2","key":"11763_CR7","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.ygyno.2015.12.007","volume":"140","author":"B Ataseven","year":"2016","unstructured":"Ataseven B, Grimm C, Harter P, et al. Prognostic impact of debulking surgery and residual tumor in patients with epithelial ovarian cancer FIGO stage IV. Gynecol Oncol. 2016;140(2):215\u201320.","journal-title":"Gynecol Oncol."},{"issue":"3","key":"11763_CR8","doi-asserted-by":"publisher","first-page":"768","DOI":"10.3390\/cancers12030768","volume":"12","author":"B Delga","year":"2020","unstructured":"Delga B, Classe JM, Houvenaeghel G, et al. 30 years of experience in the management of stage III and IV epithelial ovarian cancer: impact of surgical strategies on survival. Cancers (Basel). 2020;12(3):768.","journal-title":"Cancers (Basel)."},{"issue":"2","key":"11763_CR9","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.ejso.2008.01.005","volume":"35","author":"PE Colombo","year":"2009","unstructured":"Colombo PE, Mourregot A, Fabbro M, et al. Aggressive surgical strategies in advanced ovarian cancer: a monocentric study of 203 stage IIIC and IV patients. Eur J Surg Oncol. 2009;35(2):135\u201343.","journal-title":"Eur J Surg Oncol."},{"key":"11763_CR10","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.ejogrb.2017.02.004","volume":"211","author":"N Bourdel","year":"2017","unstructured":"Bourdel N, Chauvet P, Roman H, et al. Comparison between resection, bipolar coagulation and Plasmajet\u00ae: a preliminary animal study. Eur J Obstet. 2017;211:127\u201333.","journal-title":"Eur J Obstet"},{"key":"11763_CR11","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13048-019-0545-x","volume":"12","author":"GM Nieuwenhuyzen-De Boer","year":"2019","unstructured":"Nieuwenhuyzen-De Boer GM, Van Der Kooy J, Van Beekhuizen HJ. Effectiveness and safety of the PlasmaJet\u00ae Device in advanced stage ovarian carcinoma: a systematic review. J Ovarian Res. 2019;12:71.","journal-title":"J Ovarian Res."},{"key":"11763_CR12","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1177\/1553350620908383","volume":"27","author":"A Prodromidou","year":"2020","unstructured":"Prodromidou A, Pandraklakis A, Iavazzo C. The emerging role of neutral argon plasma (PlasmaJet) in the treatment of advanced stage ovarian cancer: a systematic review. Surg Innov. 2020;27:299\u2013306.","journal-title":"Surg Innov."},{"issue":"1","key":"11763_CR13","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.ygyno.2016.10.030","volume":"144","author":"G Cordeiro Vidal","year":"2017","unstructured":"Cordeiro Vidal G, Babin G, et al. Primary debulking surgery with a plasma device surgery system, for advanced ovarian cancer. Gynecol Oncol. 2017;144(1):223\u20134.","journal-title":"Gynecol Oncol"},{"issue":"8","key":"11763_CR14","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1097\/IGC.0000000000000788","volume":"26","author":"E Panuccio","year":"2016","unstructured":"Panuccio E, Leunen K, Van Nieuwenhuysen E, et al. Use of PlasmaJet for peritoneal carcinomatosis in ovarian cancer. Int J Gynecol Cancer. 2016;26(8):1521\u20134.","journal-title":"Int J Gynecol Cancer."},{"issue":"1","key":"11763_CR15","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/S1701-2163(15)31048-3","volume":"35","author":"MC Renaud","year":"2013","unstructured":"Renaud MC, Sebastianelli A. Optimal cytoreduction with neutral argon plasma energy in selected patients with ovarian and primitive peritoneal cancer. J Obstet Gynaecol Canada. 2013;35(1):49\u201352.","journal-title":"J Obstet Gynaecol Canada."},{"issue":"4","key":"11763_CR16","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1002\/jso.26385","volume":"123","author":"A Volcke","year":"2021","unstructured":"Volcke A, Van Nieuwenhuysen E, Han S, Salihi R, Van Gorp T, Vergote I. Experience with PlasmaJet\u2122 in debulking surgery in 87 patients with advanced-stage ovarian cancer. J Surg Oncol. 2021;123(4):1109\u201314.","journal-title":"J Surg Oncol"},{"key":"11763_CR17","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12885-019-5275-3","volume":"19","author":"GM Nieuwenhuyzen-De Boer","year":"2019","unstructured":"Nieuwenhuyzen-De Boer GM, Hofhuis W, Reesink-Peters N, et al. Evaluation of effectiveness of the PlasmaJet surgical device in the treatment of advanced stage ovarian cancer (PlaComOv-study): Study protocol of a randomized controlled trial in the Netherlands. BMC Cancer. 2019;19:58.","journal-title":"BMC Cancer."},{"issue":"9","key":"11763_CR18","first-page":"245","volume":"24","author":"TK Madhuri","year":"2014","unstructured":"Madhuri TK, Ashbourne W, Butler-Manuel SA, et al. RCT to evaluate utility and efficacy of neutral argon plasma as new technology in achieving complete cytoreduction of advanced epithelial ovarian carcinoma\u2013initial feasibility study. Int J Gynaecol Cancer. 2014;24(9):245.","journal-title":"Int J Gynaecol Cancer."},{"issue":"9","key":"11763_CR19","first-page":"1427","volume":"25","author":"T Madhuri","year":"2015","unstructured":"Madhuri T, Tailor A, Ellis P, Ashbourne W, Butler-Manuel S, Vergote I. To evaluate PlasmaJet in achieving complete cytoreduction of advanced EOC-interim results from an initial feasibility study. Int J Gynecol Cancer. 2015;25(9):1427\u20138.","journal-title":"Int J Gynecol Cancer"},{"issue":"3","key":"11763_CR20","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/j.ygyno.2014.09.007","volume":"135","author":"S Butler-Manuel","year":"2014","unstructured":"Butler-Manuel S, Lippiatt J, Madhuri TK. Interval debulking surgery following neo-adjuvant chemotherapy for ovarian cancer using neutral argon plasma (PlasmaJet (TM)). Gynecol Oncol. 2014;135(3):622.","journal-title":"Gynecol Oncol."},{"issue":"9990","key":"11763_CR21","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S0140-6736(14)62223-6","volume":"386","author":"S Kehoe","year":"2015","unstructured":"Kehoe S, Hook J, Nankivell M, et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet. 2015;386(9990):249\u201357.","journal-title":"Lancet"},{"issue":"1","key":"11763_CR22","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.ygyno.2020.01.010","volume":"157","author":"V Ghirardi","year":"2020","unstructured":"Ghirardi V, Moruzzi MC, Bizzarri N, et al. Minimal residual disease at primary debulking surgery versus complete tumor resection at interval debulking surgery in advanced epithelial ovarian cancer: a survival analysis. Gynecol Oncol. 2020;157(1):209\u201313. https:\/\/doi.org\/10.1016\/j.ygyno.2020.01.010.","journal-title":"Gynecol Oncol."},{"issue":"3","key":"11763_CR23","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1056\/NEJMoa1708618","volume":"378","author":"WJ van Driel","year":"2018","unstructured":"van Driel WJ, Koole SN, Sikorska K, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med. 2018;378(3):230\u201340.","journal-title":"N Engl J Med."},{"issue":"12","key":"11763_CR24","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1007\/s00330-010-1886-4","volume":"20","author":"R Forstner","year":"2010","unstructured":"Forstner R, Sala E, Kinkel K, Spencer JA. European Society of Urogenital R. ESUR guidelines: ovarian cancer staging and follow-up. Eur Radiol. 2010;20(12):2773\u201380.","journal-title":"Eur Radiol"},{"issue":"6","key":"11763_CR25","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1148\/rg.326125511","volume":"32","author":"S Nougaret","year":"2012","unstructured":"Nougaret S, Addley HC, Colombo PE, et al. Ovarian carcinomatosis: how the radiologistcan help plan the surgical approach. Radiographics. 2012;32(6):1775\u2013800.","journal-title":"Radiographics."},{"issue":"3","key":"11763_CR26","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.ygyno.2014.07.002","volume":"134","author":"RS Suidan","year":"2014","unstructured":"Suidan RS, Ramirez PT, Sarasohn DM, et al. A multicenter prospective trial evaluating the ability of preoperative computed tomography scan and serum CA-125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer. Gynecol Oncol. 2014;134(3):455\u201361.","journal-title":"Gynecol Oncol."},{"issue":"6","key":"11763_CR27","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1111\/1471-0528.12992","volume":"122","author":"J Borley","year":"2015","unstructured":"Borley J, Wilhelm-Benartzi C, Yazbek J, et al. Radiological predictors of cytoreductive outcomes in patients with advanced ovarian cancer. BJOG. 2015;122(6):843\u20139.","journal-title":"BJOG."},{"issue":"3","key":"11763_CR28","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1097\/IGC.0000000000000368","volume":"25","author":"MJ Rutten","year":"2015","unstructured":"Rutten MJ, van de Vrie R, Bruining A, et al. Predicting surgical outcome in patients with international federation of gynecology and obstetrics stage III or IV ovarian cancer using computed tomography: a systematic review of prediction models. Int J Gynaecol Cancer. 2015;25(3):407\u201315.","journal-title":"Int J Gynaecol Cancer."},{"key":"11763_CR29","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt333","author":"JA Ledermann","year":"2013","unstructured":"Ledermann JA, Raja FA, Fotopoulou C, Gonzalez-Martin A, Colombo N, Sessa C. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals Oncol. 2013. https:\/\/doi.org\/10.1093\/annonc\/mdt333.","journal-title":"Annals Oncol"},{"issue":"4","key":"11763_CR30","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.ajog.2019.05.006","volume":"221","author":"BL Manning-Geist","year":"2019","unstructured":"Manning-Geist BL, Hicks-Courant K, Gockley AA, et al. A novel classification of residual disease after interval debulking surgery for advanced-stage ovarian cancer to better distinguish oncologic outcome. Am J Obstet Gynecol. 2019;221(4):326.","journal-title":"Am J Obstet Gynecol."},{"issue":"10","key":"11763_CR31","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","volume":"20","author":"M Herdman","year":"2011","unstructured":"Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20(10):1727\u201336.","journal-title":"Qual Life Res."},{"issue":"1","key":"11763_CR32","doi-asserted-by":"publisher","first-page":"e10178","DOI":"10.2196\/10178","volume":"21","author":"G Hernandez","year":"2019","unstructured":"Hernandez G, Garin O, Dima AL, et al. EuroQol (EQ-5D-5L) Validity in assessing the quality of life in adults with asthma: cross-sectional study. J Med Internet Res. 2019;21(1):e10178.","journal-title":"J Med Internet Res."},{"key":"11763_CR33","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.ygyno.2013.05.040","volume":"130","author":"SJ Chang","year":"2013","unstructured":"Chang SJ, Hodeib M, Chang J, Bristow RE. Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: a meta-analysis. Gynecol Oncol. 2013;130:493\u20138.","journal-title":"Gynecol Oncol."},{"key":"11763_CR34","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1097\/IGC.0000000000000849","volume":"27","author":"EJ Tanner","year":"2017","unstructured":"Tanner EJ, Dun E, Sonoda Y, Olawaiye AB, Chi DS. A comparison of thermal plasma energy versus argon beam coagulator-induced intestinal injury after vaporization in a porcine model. Int J Gynecol Cancer. 2017;27:177\u201382.","journal-title":"Int J Gynecol Cancer."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-022-11763-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-022-11763-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-022-11763-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T06:05:07Z","timestamp":1660197907000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-022-11763-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,13]]},"references-count":34,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["11763"],"URL":"https:\/\/doi.org\/10.1245\/s10434-022-11763-2","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,13]]},"assertion":[{"value":"23 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2022","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"G. M. Nieuwenhuyzen-de Boer's name was corrected.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"I.A.B. reports translational research (ctDNA) to the employer (Erasmus MC Cancer Institute) grant by GSK. The study was funded by the Netherlands Organization for Health Research and Development (ZonMw), number 843001805. No relevant conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}},{"value":"The study is carried out according to the standards outlined in the Declaration of Helsinki. Patients from the following Dutch hospitals were included: Albert Schweitzer (Dordrecht), Bravis (Bergen op Zoom), Catharina Cancer Institute (Eindhoven), Erasmus MC (Rotterdam), Franciscus Gasthuis and Vlietland (Rotterdam), Groene Hart Hospital (Gouda), Haags Medisch Centrum (The Hague), Haga Hospital (The Hague), Leiden University Medical Center (Leiden), Maastricht UMC+ (Maastricht), Medisch Spectrum Twente (Enschede), Netherlands Cancer Institute (Amsterdam), and Reinier de Graaf Groep (Delft). Patients received verbal and written information from their gynecologists during the intake for surgery. Informed consent to use the data for analyses was obtained from all participants. Randomization took place after a patient had signed the informed consent form. All data are pseudonymized. Participants could withdraw from the study at any time without providing a reason.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval and Consent to Participate"}}]}}